Search results
Jul 5, 2019 · For major relapses, including severely damaging, potentially organ-threatening or life-threatening ANCA-associated vasculitis, rituximab or cyclophosphamide with glucocorticoids is recommended.
- Mark McClure, Rachel B. Jones
- 2019
For patients with MPA or MPO-ANCA-associated vasculitis, cyclophosphamide remains an option for remission induction because these patients respond equally well to cyclophosphamide or rituximab, and they have a much lower relapse risk than those with PR3-ANCA or GPA.
Apr 8, 2021 · The duration of maintenance therapy with AZA was studied in the prolonged Remission-Maintenance Therapy in Systemic Vasculitis (REMAIN) trial. A significant reduction of relapse rates was noted with 48 months of treatment compared to 24 months only, of 22% and 63%, respectively (p < 0.0001).
- Karla N. Samman, Carolyn Ross, Christian Pagnoux, Jean-Paul Makhzoum
- 10.1155/2021/5534851
- 2021
- Int J Rheumatol. 2021; 2021: 5534851.
1 . INTRODUCTION. tides (AAV) comprise granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic g. anu-lomatosis with polyangiitis (EGPA). These diseases affect small- and medium- sized vessels and are c. addition to vasculitis. Common clinical manifestations include destructive sinonasal lesio.
The clinical disease type (GPA vs MPA), ANCA serotype (PR3-ANCA vs MPO-ANCA) and ANCA status (positive vs negative) have all been associated with the risk of relapse.
Nov 28, 2020 · Clinical relapses are common in patients with ANCA-associated vasculitis (AAV). The aim of this systematic review was to estimate time-point prevalence and risk factors of relapse. Methods. We searched PubMed, Embase, and Cochrane Library databases from their inception to March 30, 2020.
People also ask
Can cyclophosphamide prevent relapse in ANCA-associated vasculitis?
Can avacopan be used to treat ANCA-associated vasculitis?
Can Intravenous pulse methylprednisolone induce remission in severe ANCA associated vasculitis?
May 23, 2019 · However, a return to ANCA positivity or a rising ANCA titer after induction of remission (on conventional maintenance therapy) are not reliable markers of disease relapse. As such, routine ANCA monitoring in current practice is not recommended.
